+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 99Years
MALE
ID07792993

Evaluating Moderately Hypofractionated Radiotherapy with Focal Micro-Boost for Intermediate- to High-Risk Localized Prostate Cancer in an Observational Study

Led by Regina Elena Cancer Institute · Updated on 2026-08-28

82

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a radiotherapy strategy called moderately hypofractionated micro-boost radiotherapy for men with localized intermediate- or high-risk prostate cancer. This approach aims to deliver a higher radiation dose specifically to dominant tumor areas identified by advanced MRI scans, while limiting exposure to surrounding healthy organs. The study is observational and involves patients treated at a single center, focusing on the safety and effectiveness of this targeted treatment. Participants receive standard care radiotherapy consisting of 20 treatment sessions delivered five times per week. The prostate gland receives a total dose of 62 Gy, with dominant tumor lesions receiving a focal micro-boost up to 71.3 Gy. Seminal vesicles may also be treated with 56 Gy depending on clinical risk. Treatment planning uses CT and multiparametric MRI to precisely target tumors and protect organs at risk. Radiotherapy may be delivered using advanced techniques such as VMAT or CyberKnife. During the study, data on clinical outcomes, radiological findings, treatment plans, and side effects are collected prospectively. Patients undergo routine follow-up to monitor biochemical recurrence, toxicity, survival, and metastasis over at least three years. The main measure is the rate of biochemical recurrence-free survival at three years, defined by specific PSA criteria or need for additional therapy. The study plans to enroll 82 patients over three years with a total duration of six years for observation and data analysis.

CONDITIONS

Brief Title

Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy

Research Team

G

Giuseppe Sanguineti, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here